Harvard University’s Latest Portfolio: 5 Best Biotech Stock Picks

In this article, we will look at Harvard University’s latest stock portfolio and list its 5 best biotech stock picks. If you want to explore more biotech stocks that make up the top holdings of Harvard Management, you can also read Harvard University’s Latest Portfolio: 10 Best Biotech Stock Picks.

5. Relay Therapeutics, Inc. (NASDAQ:RLAY)

Harvard Management’s Stake Value: $9,064,000

Percentage of Harvard Management’s 13F Portfolio: 1.04%

Number of Hedge Fund Holders: 17

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicines company that develops small molecule therapies for the treatment of cancer. As of September 14, Relay Therapeutics, Inc. (NASDAQ:RLAY) has gained 4.58% over the past six months.

Wall Street is bullish on Relay Therapeutics, Inc. (NASDAQ:RLAY). On September 12, H.C. Wainwright analyst Robert Burns raised his price target on Relay Therapeutics, Inc. (NASDAQ:RLAY) to $50 from $46 and reiterated a Buy rating on the shares. On September 14, JMP Securities analyst Silvan Tuerkcan raised his price target on Relay Therapeutics, Inc. (NASDAQ:RLAY) to $38 from $35 and maintained a buy-side Outperform rating on the shares.

At the close of Q2 2022, 17 hedge funds were bullish on Relay Therapeutics, Inc. (NASDAQ:RLAY) and held stakes worth $349.35 million in the company. As of June 30, Harvard Management Company’s stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) is valued at $9.06 million, which covers 1.04% of the fund’s 13F portfolio.